Francisco Valdez Lima1,2,3, Ludhmila Abrahão Hajjar4, Juliano Pinheiro Almeida4, Sergio Ramalho5, Gaspar Rogerio Chiappa6, Graziella Cipriano5, Lawrence Patrick Cahalin7, Celso Ricardo de Carvalho8, Gerson Cipriano Junior5. 1. Cancer Institute of São Paulo State, São Paulo, Brazil. limasvaldez03@gmail.com. 2. Department of Physical Therapy, University of Brasilia, Brasilia, DF, Brazil. limasvaldez03@gmail.com. 3. Sciences and Technologies in Health Program, University of Brasilia, AE, QNN 14 - Ceilândia Sul, Brasília, DF, 72220-401, Brazil. limasvaldez03@gmail.com. 4. Department of Anesthesiology, University of São Paulo, São Paulo, Brazil. 5. Department of Physical Therapy, University of Brasilia, Brasilia, DF, Brazil. 6. Graduate Program in Human Movement and Rehabilitation of University Center of Anápolis, Anápolis, Goiânia, GO, Brazil. 7. Department of Physical Therapy, University of Miami, Coral Gables, FL, USA. 8. Department of Physical Therapy, University of São Paulo, São Paulo, Brazil.
Abstract
BACKGROUND: Noninvasive Ventilation (NIV) is a well-established treatment for Acute Respiratory Failure (ARF) in hematological cancer. However, the NIV impact on mortality in patients with solid tumors is unclear. OBJECTIVE: To define the factors associated with NIV failure and mortality and to describe the mortality risk of patients with solid tumors requiring NIV for ARF treatment in the intensive care unit (ICU). METHODS: A retrospective cohort study of patients with solid tumors admitted into an ICU between Jan 2016 and Dec 2017, for cancer treatment, with ARF diagnosis that had used the NIV as first-line treatment. Our primary outcome was ICU and in-hospital mortality. The secondary outcome was NIV failure. A Cox proportional hazards regression was used to identify variables associated with mortality and NIV failure. Kaplan-Meier analyses were performed to demonstrate cumulative survival. RESULTS: A total of 226 patients with solid tumors were included. The ICU and hospital mortality rates were 57.5% and 69.5%, respectively. NIV failed in 52.2% of the patients. The use of vasopressors (HR 2.48 [95% CI: 1.43-4.30] p = 0.001), baseline lactate (HR 1.20 [95% CI: 1.07-1.35] p = 0.003), baseline PaO2/FiO2 ratio (HR1.33 [1.11-1.55] p = 0.002), and NIV success (HR0.17 [95% CI: 0.10-0.27] p = 0.005) was independently associated with hospital mortality. The use of vasopressors (HR 2.58 [95% CI: 1.41-4.73] p = 0.02), NIV duration (HR 0.93 [95% CI: 0.89-0.97] p = 0.003), and baseline lactate (HR 1.13 [95% CI: 1.06-1.20] p = 0.001) was associated with NIV failure. CONCLUSIONS: NIV failure was independently associated with an increase in both ICU and hospital mortality rates. In patients with NIV therapy indication, the duration of this intervention was associated with NIV failure.
BACKGROUND: Noninvasive Ventilation (NIV) is a well-established treatment for Acute Respiratory Failure (ARF) in hematological cancer. However, the NIV impact on mortality in patients with solid tumors is unclear. OBJECTIVE: To define the factors associated with NIV failure and mortality and to describe the mortality risk of patients with solid tumors requiring NIV for ARF treatment in the intensive care unit (ICU). METHODS: A retrospective cohort study of patients with solid tumors admitted into an ICU between Jan 2016 and Dec 2017, for cancer treatment, with ARF diagnosis that had used the NIV as first-line treatment. Our primary outcome was ICU and in-hospital mortality. The secondary outcome was NIV failure. A Cox proportional hazards regression was used to identify variables associated with mortality and NIV failure. Kaplan-Meier analyses were performed to demonstrate cumulative survival. RESULTS: A total of 226 patients with solid tumors were included. The ICU and hospital mortality rates were 57.5% and 69.5%, respectively. NIV failed in 52.2% of the patients. The use of vasopressors (HR 2.48 [95% CI: 1.43-4.30] p = 0.001), baseline lactate (HR 1.20 [95% CI: 1.07-1.35] p = 0.003), baseline PaO2/FiO2 ratio (HR1.33 [1.11-1.55] p = 0.002), and NIV success (HR0.17 [95% CI: 0.10-0.27] p = 0.005) was independently associated with hospital mortality. The use of vasopressors (HR 2.58 [95% CI: 1.41-4.73] p = 0.02), NIV duration (HR 0.93 [95% CI: 0.89-0.97] p = 0.003), and baseline lactate (HR 1.13 [95% CI: 1.06-1.20] p = 0.001) was associated with NIV failure. CONCLUSIONS:NIV failure was independently associated with an increase in both ICU and hospital mortality rates. In patients with NIV therapy indication, the duration of this intervention was associated with NIV failure.
Authors: So Young Park; So Yeon Lim; Sang-Won Um; Won-Jung Koh; Man Pyo Chung; Hojoong Kim; O Jung Kwon; Hye Kyeong Park; Seok Jin Kim; Young Hyuck Im; Myung-Ju Ahn; Gee Young Suh Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603
Authors: D M Bowie; T J Marrie; D T Janigan; A D MacKeen; P Belitsky; A S MacDonald; S G Lannon; A D Cohen Journal: Can Med Assoc J Date: 1983-06-15 Impact factor: 8.262
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702